List view / Grid view
The EMA’s decision permits WuXi Biologics to progress with commercial…
The EMA’s decision permits WuXi Biologics to progress with commercial manufacturing of a global client’s innovative biologic.
The new manufacturing site features automation capabilities to ensure efficient…
The new manufacturing site features automation capabilities to ensure efficient production and supports advancement of potential next-generation microbial therapies.
The new installation increases capacity at WuXi Biologics’ Hangzhou manufacturing…
The new installation increases capacity at WuXi Biologics’ Hangzhou manufacturing facility from 8,000L to 23,000L.
The environmentally-sustainable inaugural manufacturing run at WuXi Biologics’ GMP-certified facility…
The environmentally-sustainable inaugural manufacturing run at WuXi Biologics’ GMP-certified facility in Ireland combined four 4,000-litre single-use bioreactors.
WuXi Biologics proposed spin-off and a separate HKEX listing of…
WuXi Biologics proposed spin-off and a separate HKEX listing of its subsidiary WuXi XDC means the company will be able to better capture the fast-growing global bioconjugate market.
China’s WuXi Biologics - a contract research, development and manufacturing…
China’s WuXi Biologics - a contract research, development and manufacturing organisation (CRDMO) - has launched a facility in Hangzhou for cGMP manufacturing of microbial-derived products.
WuXi Biologics awarded the Bioprocessing Excellence in Viral Clearance and…
WuXi Biologics awarded the Bioprocessing Excellence in Viral Clearance and Safety accolade for the second time at the Asia-Pacific Bioprocessing Excellence Awards (ABEA) 2022 event.
The US NIH has initiated a clinical trial for remdesivir…
The US NIH has initiated a clinical trial for remdesivir and two pharmaceutical companies will work together to manufacture antibody treatments to tackle the coronavirus.
